Gene Editing Market Scope and Key Players Analysis by 2030
Gene Editing Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 6,542.95 Million |
Market Size by 2030 | US$ 23,902.34 Million |
Global CAGR (2022 - 2030) | 17.6% |
Historical Data | 2020-2022 |
Forecast period | 2022-2030 |
Segments Covered |
By Component
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
Industry Developments and Future Opportunities:
Various initiatives taken by key players operating in the global gene editing market are listed below:
- In April 2022, Thermo Fisher Scientific introduced the GMP-manufactured Gibco CTS TrueCut Cas9 Protein to help researchers meet stringent quality requirements while using genome editing tools. It is a promising option for CAR T-cell therapy studies using CRISPR-Cas9 genome editing as it consistently provides higher than 90% efficacy in human primary T-cells and high editing effectiveness in all examined cell lines.
Competitive Landscape and Key Companies:
Thermo Fisher Scientific; GenScript; Lonza; Merck KGaA; CRISPR Therapeutics; PerkinElmer Inc.; Agilent Technologies, Inc.; Precision Biosciences; Sangamo Therapeutics, Inc.; New England Biolabs; and Novartis are among the prominent players in the gene editing market. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.